<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3390/vaccines8030459</dc:identifier><dc:language>eng</dc:language><dc:creator>Roy, S.</dc:creator><dc:creator>Williams, C.M.</dc:creator><dc:creator>Pardo, J.</dc:creator><dc:creator>Wijesundara, D.K.</dc:creator><dc:creator>Furuya, Y.</dc:creator><dc:title>Impact of pre-existing immunity on live attenuated influenza vaccine-induced cross-protective immunity</dc:title><dc:identifier>ART-2020-120239</dc:identifier><dc:description>The efficacy of the intranasally (i.n.) delivered live attenuated influenza vaccine (LAIV) is variable and, in some seasons, suboptimal. In this study, we report that LAIV exhibits cross-protective efficacy in mice, potentially associated with cellular immunity as opposed to antigen-specific antibody responses. However, pre-exposure to the intramuscularly (i.m.) delivered inactivated influenza vaccine (IIV) severely impaired LAIV-induced cross-protection against heterologous challenge, potentially by inhibiting replication of LAIV. Our findings suggest that pre-existing immunity afforded by IIV suppresses cross-protective T cell immunogenicity of LAIV.</dc:description><dc:date>2020</dc:date><dc:source>http://zaguan.unizar.es/record/95801</dc:source><dc:doi>10.3390/vaccines8030459</dc:doi><dc:identifier>http://zaguan.unizar.es/record/95801</dc:identifier><dc:identifier>oai:zaguan.unizar.es:95801</dc:identifier><dc:identifier.citation>Vaccines 8, 3 (2020), 459 [1-6 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>